NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients interested in applying should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSFabry disease patients who rely on financial assistance to afford expensive enzyme replacement or substrate reduction therapies have lost access to this $12,000 annual benefit, making it harder to maintain continuous treatment.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help patients afford treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have hereditary angioedema and rely on financial assistance to afford your medications, you'll need to explore alternative funding sources since this major assistance program is temporarily unavailable.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new medication called LIFYORLI (relacorilant) made by Corcept Therapeutics. This drug was officially approved on March 25, 2026. LIFYORLI is a new treatment option that is now available for patients who need it.
WHY IT MATTERSThis approval marks the availability of a new treatment option for patients with Cushing's syndrome, a serious hormonal disorder where the body produces too much cortisol.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug, though the specific name and disease it treats are not listed in this announcement. The drug was developed by MAP77 and received official FDA approval on March 20, 2026. Without more details about what condition this drug treats, it's unclear how it might help patients.
WHY IT MATTERSUnable to determine specific patient impact without knowing the drug name, disease indication, or therapeutic area — this announcement lacks essential details needed to assess relevance to any particular rare disease community.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Denali Therapeutics, but the specific name and what disease it treats are not listed in this announcement. The approval was granted on March 24, 2026. Patients and doctors should look for more details from the FDA or the company to understand what this drug does and who it might help.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the clinical significance for patients — additional information from the FDA or Denali Therapeutics is needed to assess impact.
ResearchCONGRESSApr 1
Researchers studied how life circumstances like poverty, access to healthcare, and education affect children with developmental delays and intellectual disabilities. They also looked at how long it takes families to get a diagnosis and whether genetic testing helps. The study suggests that where you live and your resources matter a lot in getting answers for why a child has developmental challenges.
WHY IT MATTERSThis research highlights that children from disadvantaged backgrounds face longer diagnostic journeys for developmental delays—meaning families may wait years longer to understand their child's condition and access support services.